This finding suggests that pre-operative circulating CgA determination could have a potential role in the clinical management of PC patients and could complement the PSA assay in an early selection of more aggressive PC such as those with NE features, particularly in those patients showing a higher Gleason score. The gene discussed is CGA; the disease is pachyonychia congenita.